证券代码：301301 证券简称：川宁生物 公告编号：2025-024 根据《公司法》《深圳证券交易所上市公司自律监管指引第 2 号——创业板 上市公司规范运作》和《公司章程》的相关规定，段胜国先生的辞职报告自送达 公司董事会之日起生效。 段胜国先生在担任公司副总经理期间恪尽职守、勤勉尽责，公司及董事会对 段胜国先生任职期间为公司所做的贡献表示衷心感谢！ 特此公告。 伊犁川宁生物技术股份有限公司董事会 关于公司高级管理人员辞职的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 伊犁川宁生物技术股份有限公司（以下简称"公司"）董事会于近日收到公 司副总经理段胜国先生的书面辞职报告，段胜国先生因到龄退休提请辞去公司所 有职务，上述职务原定任期届满之日为 2026 年 5 月 4 日。辞职后将不再担任公 司其他任何职务。目前其所负责的相关工作已顺利交接，辞职后不会影响公司正 常生产经营活动。 2025 年 5 月 6 日 伊犁川宁生物技术股份有限公司 ...

Investment Rating - The report maintains a "Recommended" rating for the company [6][8]. Core Views - The company achieved a revenue of 5.76 billion yuan in 2024, representing a year-on-year growth of 19.4%, and a net profit attributable to shareholders of 1.4 billion yuan, up 48.9% year-on-year [3]. - In Q1 2025, the company reported a revenue of 1.3 billion yuan, a decline of 14.9% year-on-year, and a net profit of 290 million yuan, down 18.3% year-on-year [3][5]. - The strong performance in 2024 was driven by robust growth in the main business, particularly in pharmaceutical intermediates, with a revenue of 5.4 billion yuan, up 19.5% year-on-year [4]. - The company is expected to see improvements in performance throughout 2025, with a focus on maintaining price stability in key products and leveraging AI technology for cost reduction [5][6]. Summary by Sections Financial Performance - In 2024, the company achieved a total revenue of 5.76 billion yuan, with a net profit of 1.4 billion yuan, and a gross margin of 36.39% [7][11]. - The forecast for 2025 indicates a slight revenue increase to 5.88 billion yuan, with net profit expected to remain stable at 1.41 billion yuan [7][11]. Business Segments - The pharmaceutical intermediates segment showed strong growth, with key products like penicillin intermediates and cephalosporin intermediates experiencing significant revenue increases [4]. - The company is expanding its synthetic biology segment, with several products entering production, indicating potential for future growth [6]. Future Outlook - The company is projected to maintain stable profit levels from 2025 to 2027, with net profits of 1.41 billion yuan in 2025 and gradually increasing to 1.46 billion yuan by 2027 [6][7]. - The anticipated PE ratios for the forecasted years are 19 for 2025 and 18 for 2026 and 2027, reflecting a stable valuation outlook [7][11].

证券代码：301301 证券简称：川宁生物 公告编号：2025-022 伊犁川宁生物技术股份有限公司 第二届监事会第九次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 伊犁川宁生物技术股份有限公司（以下简称"公司"）第二届监事会第九次 会议通知于 2025 年 4 月 18 日以专人送达、电子邮件和电话通知的方式发出，会 议于 2025 年 4 月 28 日上午 11 点在公司会议室以现场表决方式召开。会议应出 席监事 3 人，实际出席监事 3 人，会议由监事会主席杨帆先生主持。本次会议的 召集和召开程序符合《中华人民共和国公司法》等有关法律、行政法规、部门规 章、规范性文件和《公司章程》的相关规定，会议形成的决议合法、有效。 二、监事会会议审议情况 经与会监事认真审议，以书面记名投票表决方式通过以下决议： （一）以 3 票同意，0 票反对，0 票弃权，审议通过了《关于审议公司 2025 年第一季度报告的议案》 监事会对公司 2025 年第一季度报告进行了认真严格的审核后认为：公司 2025 年第一季度报告的编制和审议程序符合法律、法规及《公司章 ...

证券代码：301301 证券简称：川宁生物 公告编号：2025-021 伊犁川宁生物技术股份有限公司 第二届董事会第十次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 伊犁川宁生物技术股份有限公司（以下简称"公司"）第二届董事会第十次 会议通知于 2025 年 4 月 18 日以专人送达、电子邮件和电话通知的方式发出，会 议于2025年4月28日上午10点在公司会议室以现场结合通讯的表决方式召开。 会议应出席董事 7 人，实际出席董事 7 人，会议由董事长刘革新先生主持，公司 全体监事及高级管理人员列席了会议。本次会议的召集和召开程序符合《中华人 民共和国公司法》等有关法律、行政法规、部门规章、规范性文件和《公司章程》 的相关规定，会议形成的决议合法、有效。 二、董事会会议审议情况 经与会董事认真审议，以书面记名投票表决方式通过以下决议： （一）以 7 票同意，0 票反对，0 票弃权，审议通过了《关于公司 2025 年第 一季度报告的议案》 公司董事会认真审议了《伊犁川宁生物技术股份有限公司 2025 年第一季度 报告》， ...

Financial Performance - The company's revenue for Q1 2025 was ¥1,296,949,550.16, a decrease of 14.85% compared to ¥1,523,218,164.00 in the same period last year[7] - Net profit attributable to shareholders was ¥288,218,532.72, down 18.26% from ¥352,614,874.42 year-on-year[7] - Basic earnings per share were ¥0.13, reflecting an 18.75% decline from ¥0.16 in the same quarter last year[7] - Net profit for the current period was ¥288,206,596.52, down 18.3% from ¥352,626,111.92 in the previous period[27] Cash Flow - The cash flow from operating activities decreased significantly by 56.91%, amounting to ¥116,584,540.52 compared to ¥270,569,372.13 in the previous year[15] - Operating cash inflow for the current period was $648,163,490.34, down 18.2% from $792,326,034.25 in the previous period[30] - Net cash flow from operating activities decreased to $116,584,540.52, a decline of 56.9% compared to $270,569,372.13 in the prior period[31] - Cash outflow from investment activities totaled $422,965,903.29, significantly higher than $80,063,954.60 in the previous period[31] - Net cash flow from investment activities was -$222,501,544.38, worsening from -$79,956,654.60 in the prior period[31] - Cash flow from financing activities resulted in a net outflow of -$28,751,355.04, compared to -$66,575,155.57 in the previous period[31] - The ending balance of cash and cash equivalents was $952,641,363.26, an increase from $883,122,418.32 in the previous period[32] Assets and Liabilities - Total assets increased by 1.70% to ¥10,732,543,256.83 from ¥10,553,579,961.17 at the end of the previous year[7] - Total liabilities decreased to ¥2,525,346,199.76 from ¥2,637,164,117.24, a reduction of about 4.2%[24] - Non-current liabilities decreased to ¥553,278,437.67 from ¥689,629,227.58, a drop of about 19.7%[24] - The total non-current assets decreased to CNY 6,316,164,332.27 from CNY 6,409,356,087.63, a decline of approximately 1.5%[22] Equity - The total equity attributable to shareholders increased by 3.68% to ¥8,188,380,183.44 from ¥7,897,587,034.11 at the end of the previous year[7] - The company's retained earnings increased to ¥2,349,151,220.87 from ¥2,060,932,688.15, an increase of approximately 14.0%[24] Research and Development - Research and development expenses surged by 140.34% to ¥40,094,047.08, up from ¥16,682,182.70 year-on-year, indicating a strong focus on innovation[13] - The company is focusing on expanding its market presence and enhancing its product offerings through ongoing research and development initiatives[19] Investments - The company reported a significant increase in long-term equity investments by 139.78%, reaching ¥37,895,227.74, attributed to additional capital injections into joint ventures[12] - Long-term equity investments rose to CNY 37,895,227.74 from CNY 15,804,416.14, showing a significant increase of about 139.5%[22] Operational Costs - Total operating costs decreased to ¥947,594,552.57 from ¥1,098,639,822.39, a decline of approximately 13.7%[26] - The company experienced a 106.68% rise in selling expenses, totaling ¥7,951,719.02, primarily due to increased promotional and hospitality costs[13] Miscellaneous - The company has developed new data resources, with development expenditures recorded at CNY 1,000,000.00, which was not present in the previous period[22] - The company has not disclosed any significant mergers or acquisitions during this reporting period[19] - The company did not conduct an audit for the first quarter report[33]

Core Viewpoint - Chuaning Biological achieved significant growth in 2024, with a revenue of 5.758 billion yuan, a year-on-year increase of 19.38%, and a net profit of 1.4 billion yuan, up 48.88% [1] Group 1: Financial Performance - The company reported a basic earnings per share of 0.63 yuan, reflecting a 50% year-on-year increase [1] - The growth in performance is attributed to increased sales and prices of cephalosporin products, improved production processes reducing costs, and a decrease in interest expenses due to reduced debt [1] Group 2: Technological Advancements - Chuaning Biological has integrated AI technology into its production processes, leading to a 20% reduction in production cycle time for antibiotic intermediates and a 10% decrease in costs [2] - The company invested 167 million yuan in R&D in 2024, focusing on over 10 synthetic biology pipelines, achieving breakthroughs such as the mass production of synthetic biological compound with a purity of 99.9% [2][3] Group 3: Product Portfolio and Market Outlook - The main products for 2024 include thiocyanate erythromycin, cephalosporin intermediates, penicillin intermediates, with revenue contributions of 32.35%, 24.96%, 41.95%, and 0.74% respectively [3] - Price trends indicate that thiocyanate erythromycin prices are steadily increasing, while cephalosporin prices are stable with slight fluctuations expected, and penicillin prices have stabilized after facing pressure [3][4] Group 4: AI Integration and Production Efficiency - The introduction of AI has significantly enhanced production efficiency, with an average yield increase of 3%-5% for thiocyanate erythromycin through optimized fermentation processes [4] - The company plans to extend AI technology across its entire product line, aiming to improve overall production system efficiency and build a comprehensive intelligent system covering all R&D scenarios [4]

Financial Performance - The company achieved operating revenue of 1 billion yuan in 2024, a year-on-year increase of 19.38% [2] - The net profit attributable to the parent company reached 0.48 billion yuan, growing by 14.00% year-on-year [2] - Basic earnings per share increased to 0.63 yuan, reflecting a growth of 50.00% [2] Revenue Composition - The revenue from thiocyanate erythromycin accounted for 32.35% of total revenue [2] - Cephalosporin intermediates contributed 24.96% to the main business revenue [2] - Penicillin intermediates made up 41.95% of the main business revenue [2] - Other products represented 0.74% of the main business revenue [2] Key Growth Drivers - Increased sales volume and prices of cephalosporin products contributed to the rise in net profit [3] - Continuous improvement in technology reduced production costs, leading to higher net profit [3] - A decrease in interest expenses due to reduced interest-bearing debt also supported profit growth [3] Market Outlook - The price of thiocyanate erythromycin is expected to maintain a steady upward trend [4] - Cephalosporin product prices are stabilizing after a recovery in 2024, with minor fluctuations anticipated [4] - Penicillin products faced price pressure but are expected to stabilize at current levels [4] Cost Management - The company improved production technology, increasing the yield of thiocyanate erythromycin by 5% [8] - The introduction of high-yield strains in the cephalosporin production line improved extraction rates by 3.5% [8] - Overall production costs are expected to decrease further through process optimization and multi-product production lines [8] Financial Ratios - The overall gross margin for 2024 was 36.39%, an increase of 4.82% year-on-year [9] - Financial expense ratio decreased to 0.84%, down by 0.22% year-on-year [11] Future Projections - The company anticipates stable revenue levels in the antibiotic intermediate sector for 2025, with potential profit improvements from ongoing cost reductions [9] - The synthetic biology segment aims for over 100 million yuan in revenue and a significant profit contribution [9] Strategic Initiatives - The company plans to enhance its synthetic biology capabilities, focusing on high-value products and expanding its product matrix [7] - AI technology is being integrated into production processes to optimize fermentation and improve yield [11] - The company is exploring new markets and product lines, particularly in Kazakhstan, focusing on mature bulk products [14] Risk Factors - Potential impacts from macroeconomic fluctuations, such as inflation and geopolitical tensions, could affect product demand [21] - Raw material price volatility poses a risk to profit margins, influenced by market demand and climate conditions [21]

Core Viewpoint - The company Chuaning Biological has reported significant growth in revenue and net profit, driven by increased sales and prices of its main products, as well as improvements in manufacturing processes through AI technology [1][2][3] Financial Performance - In 2024, Chuaning Biological achieved a revenue of 5.758 billion yuan, a year-on-year increase of 19.38%, and a net profit of 1.4 billion yuan, up 48.88%, both reaching historical highs [1] - The company's revenue from pharmaceutical intermediates was 5.356 billion yuan, an increase of over 900 million yuan from the previous year, with a year-on-year growth rate exceeding 20% [1] - The gross profit margin for the pharmaceutical intermediates business improved by 5.42 percentage points to 38.63% [1] Product and Market Insights - Chuaning Biological specializes in the research and sales of antibiotic intermediates, including three main categories: thiocyanate erythromycin, cephalosporin intermediates, and penicillin derivatives [1] - The revenue contribution from the three main products to total revenue was 32.35%, 24.96%, and 41.95%, respectively [1] AI and Technological Advancements - The company has begun utilizing AI to enhance manufacturing processes, achieving dynamic control in the production line of thiocyanate erythromycin, which has led to increased fermentation yields and reduced production fluctuations [2] - Chuaning Biological plans to continue leveraging AI and synthetic biology technologies to further stabilize production fluctuations and improve extraction yields by 2025 [3] Strategic Investments - In February of the previous year, Chuaning Biological acquired a 16.67% stake in Shanghai Jinchang Technology, which focuses on AI applications in biotechnology [2]

Group 1 - The company raised a total of RMB 1,114 million through the issuance of 222,800,000 shares at a price of RMB 5.00 per share, with a net amount of RMB 1,021.68 million after deducting expenses [2][5][16] - As of December 31, 2024, the company has invested a total of RMB 910.22 million from the raised funds, with specific allocations including RMB 188.54 million for the Shanghai Research Institute project and RMB 196.68 million for the Green Circular Industry Park project [5][16] - The company has established special accounts for the management of raised funds, ensuring compliance with regulatory requirements and protecting investor interests [6][7] Group 2 - The company has adjusted the implementation method of the Shanghai Research Institute project from leasing to purchasing, increasing the investment amount from RMB 200 million to RMB 300 million, with an additional RMB 100 million sourced from over-raised funds [12][13] - The company reported no idle raised funds used for temporary working capital during the reporting period [10] - The company has confirmed that the disclosure of the use of raised funds aligns with actual usage, with no violations reported [13][14] Group 3 - The company plans to distribute a cash dividend of RMB 2.70 per 10 shares, totaling RMB 601.33 million, which represents 42.94% of the net profit attributable to shareholders for the year 2024 [48][49] - The profit distribution plan has been approved by the board and will be submitted for shareholder approval [50][51] - The company will not conduct a capital reserve transfer to increase share capital in 2024 [49]

Core Viewpoint - Chuaning Bio reported a positive overall business performance for the fiscal year 2024, with significant growth in revenue and net profit, driven by increased sales and improved production efficiency [1][2] Financial Performance - The company achieved an operating income of 5.758 billion yuan, representing a year-on-year increase of 19.38% [1] - Net profit attributable to shareholders reached 1.4 billion yuan, up 48.88% year-on-year [1] - Basic earnings per share were 0.63 yuan, reflecting a growth of 50.00% compared to the previous year [1] Business Segments - The main business revenue breakdown includes: - Erythromycin thiocyanate: 32.35% - Cephalosporin intermediates: 24.96% - Penicillin intermediates: 41.95% - Other products: 0.74% [1] Strategic Development - The company adheres to a "dual-drive" strategy focusing on "biological fermentation" and "synthetic biology" [1][2] - Chuaning Bio has become a leading enterprise in the global biological fermentation technology industry, maintaining stable growth in product orders and prices [2] Investment and Innovation - The company invested 60 million yuan in a private equity fund to enhance its competitive edge and resource allocation [2] - A strategic partnership with Shanghai Jinchang Technology was established to integrate AI into fermentation and synthetic biology research, aiming to improve production efficiency and reduce costs [3] Future Outlook - Chuaning Bio plans to continue its "dual-drive" strategy, leveraging AI technology to maintain its leading position in the biological fermentation sector [4] - The company announced a profit distribution plan, proposing a cash dividend of 2.70 yuan per 10 shares, with total dividends since listing amounting to 1.3 billion yuan [4]